These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 26230354)

  • 1. Factors affecting the success of next-generation sequencing in cytology specimens.
    Roy-Chowdhuri S; Goswami RS; Chen H; Patel KP; Routbort MJ; Singh RR; Broaddus RR; Barkoh BA; Manekia J; Yao H; Medeiros LJ; Staerkel G; Luthra R; Stewart J
    Cancer Cytopathol; 2015 Nov; 123(11):659-68. PubMed ID: 26230354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utilization of cytology smears improves success rates of RNA-based next-generation sequencing gene fusion assays for clinically relevant predictive biomarkers.
    Ramani NS; Chen H; Broaddus RR; Lazar AJ; Luthra R; Medeiros LJ; Patel KP; Rashid A; Routbort MJ; Stewart J; Tang Z; Bassett R; Manekia J; Barkoh BA; Dang H; Roy-Chowdhuri S
    Cancer Cytopathol; 2021 May; 129(5):374-382. PubMed ID: 33119213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accuracy of next-generation sequencing for the identification of clinically relevant variants in cytology smears in lung adenocarcinoma.
    Baum JE; Zhang P; Hoda RS; Geraghty B; Rennert H; Narula N; Fernandes HD
    Cancer Cytopathol; 2017 Jun; 125(6):398-406. PubMed ID: 28272845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of Factors Affecting the Success of Next-Generation Sequencing Testing in Solid Tumors.
    Goswami RS; Luthra R; Singh RR; Patel KP; Routbort MJ; Aldape KD; Yao H; Dang HD; Barkoh BA; Manekia J; Medeiros LJ; Roy-Chowdhuri S; Stewart J; Broaddus RR; Chen H
    Am J Clin Pathol; 2016 Feb; 145(2):222-37. PubMed ID: 27124905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preanalytic Variables in Cytology: Lessons Learned From Next-Generation Sequencing-The MD Anderson Experience.
    Roy-Chowdhuri S; Stewart J
    Arch Pathol Lab Med; 2016 Nov; 140(11):1191-1199. PubMed ID: 27333361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Next-generation sequencing of cytologic preparations: An analysis of quality metrics.
    Hwang DH; Garcia EP; Ducar MD; Cibas ES; Sholl LM
    Cancer Cytopathol; 2017 Oct; 125(10):786-794. PubMed ID: 28727266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytology smears as excellent starting material for next-generation sequencing-based molecular testing of patients with adenocarcinoma of the lung.
    Velizheva NP; Rechsteiner MP; Wong CE; Zhong Q; Rössle M; Bode B; Moch H; Soltermann A; Wild PJ; Tischler V
    Cancer Cytopathol; 2017 Jan; 125(1):30-40. PubMed ID: 27636102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimizing the DNA yield for molecular analysis from cytologic preparations.
    Roy-Chowdhuri S; Chow CW; Kane MK; Yao H; Wistuba II; Krishnamurthy S; Stewart J; Staerkel G
    Cancer Cytopathol; 2016 Apr; 124(4):254-60. PubMed ID: 26630358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors Impacting Clinically Relevant RNA Fusion Assays Using Next-Generation Sequencing.
    Ramani NS; Patel KP; Routbort MJ; Alvarez H; Broaddus R; Chen H; Rashid A; Lazar A; Lucas FAS; Yao H; Manekia J; Dang H; Barkoh BA; Medeiros LJ; Luthra R; Roy-Chowdhuri S
    Arch Pathol Lab Med; 2021 Nov; 145(11):1405-1412. PubMed ID: 33493304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lung cancer adrenal gland metastasis: Optimal fine-needle aspirate and touch preparation smear cellularity characteristics for successful theranostic next-generation sequencing.
    Gleeson FC; Kipp BR; Levy MJ; Voss JS; Campion MB; Minot DM; Tu ZJ; Klee EW; Lazaridis KN; Kerr SE
    Cancer Cytopathol; 2014 Nov; 122(11):822-32. PubMed ID: 25045116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytology smears for DNA extraction: Practical approach for selecting the best slide.
    Gupta N; Brenkert R; Lee JW; Klein M; Spitzer S; Chau K; Das K
    Cytopathology; 2019 Jan; 30(1):68-73. PubMed ID: 30055110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of major factors associated with failed clinical molecular oncology testing performed by next generation sequencing (NGS).
    Al-Kateb H; Nguyen TT; Steger-May K; Pfeifer JD
    Mol Oncol; 2015 Nov; 9(9):1737-43. PubMed ID: 26071350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Performance of next-generation sequencing on small tumor specimens and/or low tumor content samples using a commercially available platform.
    Morris SM; Subramanian J; Gel ES; Runger GC; Thompson EJ; Mallery DW; Weiss GJ
    PLoS One; 2018; 13(4):e0196556. PubMed ID: 29702695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted Next Generation Sequencing as a Reliable Diagnostic Assay for the Detection of Somatic Mutations in Tumours Using Minimal DNA Amounts from Formalin Fixed Paraffin Embedded Material.
    de Leng WW; Gadellaa-van Hooijdonk CG; Barendregt-Smouter FA; Koudijs MJ; Nijman I; Hinrichs JW; Cuppen E; van Lieshout S; Loberg RD; de Jonge M; Voest EE; de Weger RA; Steeghs N; Langenberg MH; Sleijfer S; Willems SM; Lolkema MP
    PLoS One; 2016; 11(2):e0149405. PubMed ID: 26919633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The diagnostic utility of next-generation sequencing on FNA biopsies of melanocytic uveal lesions.
    Han LM; Khanafshar E; Afshar AR; Calkins SM
    Cancer Cytopathol; 2020 Jul; 128(7):499-505. PubMed ID: 32196967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Poor cell block adequacy rate for molecular testing improved with the addition of Diff-Quik-stained smears: Need for better cell block processing.
    Harada S; Agosto-Arroyo E; Levesque JA; Alston E; Janowski KM; Coshatt GM; Eltoum IA
    Cancer Cytopathol; 2015 Aug; 123(8):480-7. PubMed ID: 25955105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using "residual" FNA rinse and body fluid specimens for next-generation sequencing: An institutional experience.
    Wei S; Lieberman D; Morrissette JJ; Baloch ZW; Roth DB; McGrath C
    Cancer Cytopathol; 2016 May; 124(5):324-9. PubMed ID: 26682952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted deep sequencing of effusion cytology samples is feasible, informs spatiotemporal tumor evolution, and has clinical and diagnostic utility.
    Leichsenring J; Volckmar AL; Kirchner M; Kazdal D; Kriegsmann M; Stögbauer F; Bockmayr T; Klauschen F; Herth FJF; Penzel R; Warth A; Schirmacher P; Endris V; Stenzinger A
    Genes Chromosomes Cancer; 2018 Feb; 57(2):70-79. PubMed ID: 29044880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Next-generation sequencing in residual liquid-based cytology specimens for cancer genome analysis.
    Yamaguchi T; Akahane T; Harada O; Kato Y; Aimono E; Takei H; Tasaki T; Noguchi H; Nishihara H; Kamata H; Tanimoto A
    Diagn Cytopathol; 2020 Nov; 48(11):965-971. PubMed ID: 32511899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Next-Generation Sequencing and Fluorescence in Situ Hybridization Have Comparable Performance Characteristics in the Analysis of Pancreaticobiliary Brushings for Malignancy.
    Dudley JC; Zheng Z; McDonald T; Le LP; Dias-Santagata D; Borger D; Batten J; Vernovsky K; Sweeney B; Arpin RN; Brugge WR; Forcione DG; Pitman MB; Iafrate AJ
    J Mol Diagn; 2016 Jan; 18(1):124-30. PubMed ID: 26596524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.